Can Regeneron Stock Hit $1,400?

REGNYTD+23.9%SPYYTD+9.4%XLVYTD+22.9%
Analyze REGN →

For questions about this article or underlying research, email help@trefis.com.

Regeneron Pharmaceuticals (REGN) stock would have to rise about 47% from its November 16, 2026 close to reach $1,400. The answer depends mostly on whether Regeneron’s revenue keeps growing near the 18.6% it managed over the twelve months to September 30, 2026. Our scenario trims that pace to 15.8% a year. So what would three more years of growth at that rate make the shares worth?

Image from Pixabay

What Could Regeneron Shares Be Worth In Three Years?

Under these assumptions, Regeneron stock would be worth about $1,517 a share three years from now, compared with $952.40 at the November 16 close. The table sets today’s figures beside the scenario’s.

Today In three years (scenario)
Revenue $16.9 billion $26.2 billion
Net margin 28.5% 29.2%
Earnings $4.82 billion $7.67 billion
P/E 20.1 20.1
Share price $952.40 $1,516.53

Almost all of that gain, 94.6%, comes from selling more: the P/E stays at today’s level in the scenario, and the net margin rises only slightly. The largest part of Regeneron’s revenue is its share of the profits from drugs it sells with Sanofi, led by Dupixent. Including that profit share, collaboration revenue was $7.33 billion in fiscal 2025, 51.1% of the company’s total.

That business is still growing. Collaboration revenue reached an all-time high of $2.7 billion in fiscal Q3 2026, management said on the October 30 call, and U.S. Dupixent sales grew 40% to $5 billion. Management credited the rise in Regeneron’s share of those profits to Dupixent’s growth and to the end of a repayment owed to Sanofi, completed in the second quarter. With the repayment over, it will not lift collaboration revenue a second time.

Regeneron’s Eye Drug Sales Were About Flat

U.S. sales of EYLEA HD and the older EYLEA came to $1.1 billion in fiscal Q3 2026, down 1% from a year earlier. EYLEA HD grew 62% to $699 million, while EYLEA fell 41% to $400 million.

For the eye drugs to add to Regeneron’s growth, EYLEA HD’s gains must outpace EYLEA’s fall, which they did not quite do in the third quarter. Management expects EYLEA HD sales to rise about 10% in the fourth quarter from the third, and demand for EYLEA to drop by a low- to mid-teens percentage. Management provided no revenue guide for fiscal 2026 as a whole, detailing only a $1 billion upfront payment from Sanofi that it expects to book as collaboration revenue in the fourth quarter, a single payment rather than a growth pace.

How Does Regeneron’s Upside Change In Other Scenarios?

The scenario’s growth pace comes from one fast year: before it, Regeneron’s revenue grew 2.9% in the twelve months to September 2025 and 5.7% in the twelve months to September 2024. The net margin starts low, too: 28.5% over the latest twelve months, against an average of 30.9% at the twelve earlier quarter-ends, from September 2023 to June 2026. The table shows the upside with one assumption changed at a time.

If instead Upside
Nothing changes (the scenario) 59.2%
Revenue growth of 13.8% a year instead of 15.8% 51.1%
Net margin of 30.9% in year three instead of 29.2% 68.4%
5 years at the same assumptions instead of 3 113.5%

A net margin returning to its own average would add to the upside, and slower revenue growth would take some of it away.

Revenue could shrink about 0.8% a year, compared with growth of 18.6% over the past twelve months, before three years of owning the stock return nothing. The net margin could fall to 18.4%, matching Regeneron’s lowest twelve-month net margin at any quarter-end from fiscal Q4 2016 on. The P/E could drop to 12.6, close to the 12.4 the stock traded at on June 30, 2025.

So far, Regeneron’s Sanofi profits are still growing, while its U.S. eye drug sales remain about flat. Combined U.S. sales of EYLEA HD and EYLEA are the measure to watch when Regeneron reports its fourth quarter, expected in January 2027. Reading a company one business at a time is how we built a strategy we are proud of, and if you have a better way to read Regeneron, we want to hear it.

Found A Better Strategy? We’d Love To Learn.

Ours is the Trefis High Quality (HQ) Portfolio: 30 quality stocks in equal weight. Since its September 2020 launch it has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000. If yours has done better, tell us about it. If not, come take a look.

See The HQ Portfolio

Spot an error or want more like this? Tell us in 10 seconds.